CRP and anemia (phenotype): An important contribution of the current findings is considering pharmacological thromboprophylaxis in the studied population, especially in those with a history of VTE prior to MPMs diagnosis, metastatic first primary malignancy, severe anemia, elevated CRP, poor ECOG at the time of MPMs diagnosis, and patients on chemotherapy.